Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 5/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | BCR | P11274 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 2/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
| ▸ | BPGM | P07738 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | CDK9 | P50750 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16206052 | 0.93 | RXRA (0.35) | PIK3CAROCK2RXRAGRIN1GRIN2B | |
| SCHEMBL17614566 | 0.92 | MEN1 (0.37) | PIK3CAMEN1KMT2AROCK2RXRA | |
| SCHEMBL17615146 | 0.92 | ROCK2 (0.38) | PIK3CAMEN1KMT2AROCK2MAPT | |
| SCHEMBL17614564 | 0.90 | KMO (0.41) | PIK3CAABL1BCRRXRAGRIN1 | |
| SCHEMBL16206042 | 0.87 | PIK3CA (0.38) | PIK3CAROCK2BRD4CDK9 | |
| SCHEMBL16206095 | 0.86 | HTR7 (0.34) | GRM2MAPTSMN1; SMN2 | |
| SCHEMBL17614559 | 0.84 | MAPT (0.33) | MEN1KMT2AABL1BCRMAPT | |
| SCHEMBL17614570 | 0.84 | TSHR (0.31) | — | |
| SCHEMBL16206082 | 0.84 | RXRA (0.34) | RXRAGRIN1GRIN2B | |
| SCHEMBL16206113 | 0.83 | CDK9 (0.36) | ABL1GRM2BRD4CDK9SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9867372-B2 | Tetrazolinone compound and use of same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-01-16 | — | — | US | disclosed |
| US-20160081339-A1 | TETRAZOLINONE COMPOUND AND USE OF SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160081339-A1 | TETRAZOLINONE COMPOUND AND USE OF SAME | MT-CO1, SOD1, MT-CO2 | PIK3CA 4099/4885MEN1 2582/4885KMT2A 2241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.